AMEX · RGNT
Healthcare · Medical - Instruments & Supplies
$2.10
Up+$0.04 (+1.94%)
Updated Aug 24, 2026, 8:57 AM
SID Score
3.1/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance
1M range · 20 trading sessions · Daily adjusted prices
RGNT closed at $2.10 after 20 trading sessions, up 1.94% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Aug 21, 2026 | $2.05 | $2.17 | $2.05 | $2.10 | 38.16K |
| Aug 20, 2026 | $2.14 | $2.2199 | $2.06 | $2.06 | 46.03K |
| Aug 19, 2026 | $2.00 | $2.47 | $1.98 | $2.23 | 197.67K |
| Aug 18, 2026 | $1.99 | $2.03 | $1.95 | $1.99 | 51.65K |
| Aug 17, 2026 | $2.04 | $2.0649 | $2.01 | $2.04 | 51.03K |
| Aug 14, 2026 | $1.91 | $2.03 | $1.90 | $2.00 | 55.19K |
| Aug 13, 2026 | $1.96 | $2.01 | $1.90 | $1.90 | 29.27K |
| Aug 12, 2026 | $1.80 | $1.9699 | $1.80 | $1.94 | 45.58K |
| Aug 11, 2026 | $1.86 | $1.93 | $1.82 | $1.84 | 41.9K |
| Aug 10, 2026 | $1.84 | $1.905 | $1.80 | $1.85 | 19.94K |
| Aug 7, 2026 | $2.04 | $2.04 | $1.855 | $1.89 | 43.62K |
| Aug 6, 2026 | $2.06 | $2.0602 | $1.97 | $1.97 | 36.36K |
| Aug 5, 2026 | $2.06 | $2.27 | $1.98 | $2.07 | 112.29K |
| Aug 4, 2026 | $1.87 | $2.1489 | $1.87 | $2.06 | 115.67K |
| Aug 3, 2026 | $1.74 | $1.99 | $1.7001 | $1.87 | 146.43K |
| Jul 31, 2026 | $1.79 | $1.9069 | $1.73 | $1.74 | 128.89K |
| Jul 30, 2026 | $1.81 | $1.88 | $1.77 | $1.80 | 69.71K |
| Jul 29, 2026 | $1.78 | $1.87 | $1.7232 | $1.78 | 53.36K |
| Jul 28, 2026 | $2.00 | $2.00 | $1.721 | $1.78 | 123.06K |
| Jul 27, 2026 | $2.00 | $2.18 | $1.98 | $2.06 | 70.35K |
The latest Smart Investors Daily articles mentioning RGNT.
RGNT research
Company profile and research snapshot.
Regentis Biomaterials Ltd is a regenerative medicine company dedicated to developing tissue repair solutions that restore health and enhance the quality of life of patients. It is focused on orthopedic treatments using its Gelrin platform based on degradable hydrogel implants to regenerate damaged or diseased tissue (inflamed cartilage and bone tissue). Gelrin is a hydrogel matrix of polyethylene glycol diacrylate (a polymer involved in tissue engineering) and denatured fibrinogen (a biologically inactivated protein that normally has a role in blood clotting). Its product is GelrinC, a cell-free, off-the-shelf hydrogel that is cured into an implant in the knee for the treatment of painful injuries to articular knee cartilage.
Visit company websiteConsensus and target data currently published for this company.
No generated briefing is available yet.
Benzinga · Jul 20, 2026
Patent expands intellectual property protection in one of the world's largest cartilage repair marketsGelrinC is a cell-free hydrogel delivered in a single ~10-minute procedure eliminating the need for cell
Benzinga · Jul 15, 2026
The approval comes as Regentis prepares for the commercial launch of GelrinC® in Europe, enabling the Company to manufacture commercial product using a process that increases production yield by approximately 400%,
Yahoo · Feb 19, 2026
Dr. Reske has proven leadership in clinical development and regulatory affairs following key role in FDA approval of cartilage repair product Agili-C leading to CartiHeal's $330 million acquisition HERZLIYA, ISRAEL / ACCESS Newswire / February 19, ...
Yahoo · Feb 17, 2026
With CE Mark approval, GelrinC is slated for commercial launch in Europe in 2026 New clinical sites to support engagement with leading orthopedic surgeons and centers of excellence in key European markets, strengthening Regentis' positioning for commercial ...
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning RGNT.
No results
No recent SID articles mention RGNT.
